Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1998-07-07
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 514908, 530385, 530829, A61K 3842, A61K 3817, C07K 1447, C07K 14805
Patent
active
057768986
ABSTRACT:
A method is disclosed treating a tumor in a host by administering a nonemulsified ultrapurified polymerized hemoglobin solution to the host and also administering a chemotherapeutic agent to the host. In a particularly preferred embodiment, the hemoglobin is bovine hemoglobin.
REFERENCES:
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5158536 (1992-10-01), Sekins et al.
patent: 5296465 (1994-03-01), Rausch et al.
patent: 5478806 (1995-12-01), Nho
Yanai et al., "Antitumor Effect of Arterial Administration of a Medium-Chain Triglyceride Solution of an Angiogenesis Inhibitor". . . Pharm. Res. 12(S) 653-657 1995.
Kato et al., "Enhanced Suppresion of Tumor Growth . . . "Cancer Res. 54 5143-5147 1994.
Teicher, B. A., et al., "Perfluorochemical Emulsions Can Increase Tumor Radiosensitivity,"Science, 223:934-936 (1984).
Chang, T.M.S., "Red Blodd Cell Substitutes: Microencpsulated Hemoglobin and Cross-Linked Hemoglobin Including Pyridoxylated Polyhemoglobin & Conjugated Hemoglobin," Biomat., Art. Cells, Art. Org., 16(1-3) :11-29 (1988).
De Venuto, F., "Evaluation of Human and Bovine Modified-Hemoglobin Solution as Oxygen-Carrying Fluid for Blood Volume Replacement," Biomat., Art. Cells, Art. Org., 16(1-3) :77-83 (1988).
Bucci, E., et al., "Bovine Hemoglobin as a Basis for Artificial Oxygen Carriers," Biomat., Art. Cells, Art. Org., 16(1-3) :197-204 (1988).
Teicher, B.A., et al., "Effect of Various Oxgenation Conditions and Fluorosol .sup.R -DA on Cancer Chemotherapeutic agents," Biomat., Art. Cells, Art. Org., 16(1-3) :533-546 (1988).
Teicher, B.A., et al., "Effect of Oxygen Level on the Enhancement of Tumor Response to Radiation by Perfluorochemical Emulsions ) (PFCES) OR Hemoglobin," Int. J. Rad. Oncol. Biol. Physic, 19:137 (1990) (Abstract).
Teicher, B.A., et al., "Combination Treatment with a Purified Hemoglobin Preparation and Antitumor Alkylating Agents (AA) I the FSaIIC Fibrosarcoma," Proc. Am. Assoc. Cancer Res., 32:387 (1991) (Abstract 2302).
Teicher, B. A., et al., "Effect of a Bovine Hemoglolin Prepartion (PBHS) on the Response of Two Murine Solid Tumors to Radiation Therapy and Chemothrapeutic Alkylating Agents," Biomat., Art. Celss, Art. Org., 19(2) :491 (1991) (Abstract).
Teicher, B.A., et al., "Effect of Oxygen Level on the Enhancement of Tumor Response to Radiation by Perfluorochemical Emulsions or a Bovine Hemoglobin Preparation," Int. J. Radiation Oncology Biol. Phys., 21:969-974 (1991).
Teicher, B.A., et al., "Influence of Scheduling, Dose, and Volume of Administration of a Perfluorochemical Emulsion on Tumor Response to Radiation Therapy," Int. J. Radiat. Oncol. Biol. Phys., 19:945-951 (1990).
Teicher, B.A., et al., "Approaches to Defining the Mechanism of Enhancement by Fluosol-DA 20% with carbogen of Melphalan Antitumor Activity," Cancer Research, 47:513-518 (Jan. 15, 1987).
Teicher, B.A., et al., "Combination Treatment with a Purified Hemoglobin Preparation and Antitumor Alkylating Agents (AA) In the FSaIIC Fibrosarcoma," Proc. Annu. Meet. Am. Assoc. Cancer Res., 32:A2302 (1991).
"Potentiation of Neoplasm Inhibitor Activity by Perfluorocarbon Emulsions," Chemical Abstracts, CA101(23): 204312S, (Jul. 27,1984).
Teicher, B.A., et al., "Increased Efficiency of Chemo-and Radio-Therapy by a Hemoglobin Solution in the 9L Gliosarcoma," in vivo, vol. 9, No. 1, 11-18 (Mar. 1995).
Holden, S.A., et al., "Increased Efficacy of Chemo-and Radio-Therapy by a Hemoglobin Solution in the 9L Gliosarcoma," from 43rd Mtg. Radiat. Res. Soc/North Amer. Hyperthermia Soc., San Jose, CA, Apr. 1995,Abstract No. P25-391, p.202.
Teicher, B.A., "Therapeutic Approaches Involving Oxygen Delivery and Antiangiogenic Agents," Proceedings of the American Association for Cancer Research, 35:663-664 (1994).
Teicher, B.A., "Increase in Tumor Oxygenation by Antiangiogenesis and Oxygen Delivery Agents as Determined by Electrode Measurements," from 43rd Mtg. Radiat. Res. Soc/North Amer. Hyperthermia Soc., San Jose, CA, Apr. 1995, Abstract No. S31-2, p. 103.
Teicher, B.A., et al., "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents," Int. J. Cancer, 57:920-925 (1994).
Teicher, B.A., et al., "Minocycline as a Modulator of Chemotherapy and Hyperthermia in Vitro and in Vivo," Cancer Lettters, 82:17-25 (1994).
Teicher, B.A., et al., "Response of FSaII Fibrosarcoma to Antiangiogenic Modulators plus Cytoxic Agents," Anticancer Research, 13:2101-2106 (1993).
Teicher, B.A., et al., ".beta.-Cyclodextrin Tetradecasulfate/Tetrahydrocortisol .+-. Minocycline as Modulators of Cancer Therapies in Vitro and in Vivo Against Primary and Metastatic Lewis Lung Carcinoma," Cancer Chemother. Pharmaol., 33:229-238 (1993).
Teicher, B.A., et al., "Effect of a Bovine Hemoglobin Preparation on the Response of the FSaIIC Fibrosarcoma to Chemotherapeutic Alkylating Agents," J. Cancer Res. Clin. Oncol., 118:123-128 (1992).
Teicher, B.A., et al., "Fluosol-DA/Carbogen with Lonidamine or Pentoxifylline as Modulators of Alkylating Agents in the FSaIIC Fibrosarcoma," Cancer Chemother. Pharmacol., 28:45-50. (1991).
Teicher, B.A., et al., "Classification of Antineoplastic Treatments by Their Differential Toxicity Toward Putative Oxygenated and Hypoxic Tumor Subpopulations in Vivo in the FSaIIC Murine Fibrosrcoma," Cancer Research, 50:3339-3344 (1990).
Gruber, M. et al., "Phase I/II Study of Fluosol.RTM./O.sub.2 in Combination with BCNU in Malignant Glioma". From Proceedings of the American Association for Cancer Research, 31:190 (1990) , Abstract No. 1129.
Meyers, F., et al. "Phase I/II Study of Fluosol.RTM./Oxygen in Combination With Weekly 5-Fluorouracil (5FU) in Metastatic Colorectal Carcinoma". From Proceedings of the American Association for Cancer Research, 30:256 (1989) , Abstract No. 1020.
Garewal, H., "Fluosol.RTM./Oxygen in Combination with Cyclophosphamide in Advanced Non-Small Cell Lung Carcinoma (NSCLC) : Phase I Results." From Proceedings of the American Association for Cancer Research, 30:371 (1989) , Abstract No. 1078.
Martin, D.F. et al., "Potentiation of Rat Brain Tumor Therapy by Fluosol and Carbogen," NCI Monographs, NCI Monographs, 6:119-122 (1988).
Teicher, B.A., "Efficacy of Bleomycin with Hyperbaric Oxygen or Extended Carbogen Breathing in the Presence and Absence of Fluosol-DA." From Proceedings of AACR, 29:483 (1988) , Abstract No. 1919.
Teicher, B.A., et al., "Effect of Fluosol-DA/Carbogen on Etoposide/Alkylating Agent Antitumor Activity," Cancer Chemother. Pharmacol., 21:281-285 (1988).
Teicher, B.A., et al., "Effects of Fluosol-DA and Oxygen Breathing on Adriamycin Antitumor Activity and Cardiac Toxicity in Mice," Cancer, 61(11) : 2196-2201 (1988).
Teicher, B.A., et al., "The Effect of Fluoson-DA and Oxygentaion Status on the Activity of Cyclophosohamide in Vivo," Cancer Chemother. Pharmacol., 21:286-291 (1988).
Teicher, B.A., et al., "Effect of Fluosol-DA.RTM. on the Response of Intracranial 9L Tumors to X Rays and BCNU," Int. J. Radiation Oncology Biol. Phys., 15:1187-1192 (1988).
Teicher, B.A., et al., "Effects of Various Oxygenation Conditions on the Enhancement by Fluosol-DA of Melphalan Antitumor Activity," Cancer Research, 47:5036-5041 (1987).
Teicher, B.A., and Holden, S.A., "Survey of the Effect of Adding Fluosol-DA 20%/O.sub.2 to Treatment With Various Chemotherapeutic Agents," Cancer Treatment Reports, 71(2) :173-177 (1987).
Teicher, B.A., "Use of Fluosol-DA.RTM.on Cancer Therapy," Int. Med. Specialist, 8:190-199 (1987).
Teicher, B.A., et al., "Effect of Fluosol-DA/O.sub.2 on Tumor-Call and Bone-Marrow Cytoxicity of Nitrosoureas in Mice Bearing FSA-11 Fibrosarcoma," Int. J. Cancer, 38:285-288 (1986).
Teicher, B.A., et al., "Effect of Fluosol-DA/O.sub.2 on the Antitumor Activity and Pulmonary Toxicity of Bleomycin," Cancer Chemother. Pharmacol., 18:213-218 (1986).
Teciher, B.A., et al., "Differential Enhancement of Melphalan Cytotoxicity in Tumor and Normal Tissue by Fluosol-DA.RTM. and Oxygen Breathing," Int. J. Cancer: 36:585-589 (1985).
Teicher, B.A., et al., "Effect of Oxygen on the Cytoxicity and Antitumor Activity of Eptoposide," JNCI, 75(6) :11
Hopkins, II Robert E.
Rausch Carl W.
Teicher Beverly A.
Biopure Corporation
Dana-Farber Cancer Institute
Degen Nancy
LandOfFree
Method for treating a tumor with a chemotherapeutic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a tumor with a chemotherapeutic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a tumor with a chemotherapeutic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1205924